Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05369494
Other study ID # AL49
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 7, 2022
Est. completion date November 18, 2023

Study information

Verified date April 2024
Source Abbott Nutrition
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this non-randomized, multi-center study is to evaluate the growth, tolerance and compliance of an extensively hydrolyzed infant formula in an intended use population of infants.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date November 18, 2023
Est. primary completion date June 23, 2023
Accepts healthy volunteers No
Gender All
Age group 0 Days to 90 Days
Eligibility Inclusion Criteria: - Infant is 0 to 90 days of age at enrollment. - Formula-fed Infant who is either experiencing persistent feeding intolerance, symptoms of suspected food protein allergy or currently consuming an extensively hydrolyzed formula (EHF) for symptoms of suspected food protein allergy, persistent feeding intolerance symptoms or other conditions where EHF is deemed an appropriate feeding by their health care professional - Parent(s) of infants confirm their intention not to administer prescription medications, OTC medications, home remedies, prebiotics, probiotics, herbal preparations or rehydration fluids that might affect GI tolerance, unless their infants are currently consuming and have been directed by their healthcare professional to continue their use during the study - Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study. - Parent(s) confirm their intention not to administer solid foods or juices to their infant from enrollment through the duration of the study - Parent(s) confirm their intention not to administer vitamin or mineral supplements (with the exception of Vitamin D supplements) to their infant from enrollment through the duration of the study, unless instructed otherwise by their healthcare professional - Infant's parent(s) or a LAR has voluntarily signed and dated an informed consent form (ICF) approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study Exclusion Criteria: - An adverse maternal, fetal or participant medical history that is thought by the investigator to have potential for effects on growth, and/or development - Awareness of a positive drug screen in the mother or participant - Suspected maternal substance abuse including alcohol - Participation in another study that has not been approved as a concomitant study by AN - Participant is receiving oral or inhaled steroids - Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent - Participant has received an amino acid-based formula

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Hydrolyzed protein infant formula with oligosaccharides
Hydrolyzed protein infant formula with oligosaccharides

Locations

Country Name City State
United States Meridian Clinical Research 3357 Charleston South Carolina
United States Javara Inc. Fayetteville Georgia
United States Gentle Pediatrics Houston Texas
United States Meridian Clinical Research 3259 Macon Georgia
United States AdventHealth Medical Group Pediatrics Orange City Florida
United States Springs Medical Research Owensboro Kentucky
United States Meridian Clinical Research, LLC Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Abbott Nutrition

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Parent Perspectives Questionnaire Parent completed questionnaire; 4, 5-point Likert scale questions, scaled from negative to positive with higher scores indicating better perception Study Day1 to Study Day 28
Other Formula Satisfaction Questionnaire Parent completed questionnaire; 13 questions of up to 5 categories, scaled from positive to negative Study Day1 to Study Day 28
Other Infant Feeding and Stool Patterns Questionnaire Parent completed questionnaire; 16, 5-point Likert scale questions, scaled from always to never Study Day1 to Study Day 28
Other Health Care Utilization Number of Visits Study Day1 to Study Day 28
Other Adverse Events Parent reported adverse events Study Day1 to Study Day 28
Primary Weight Maintenance Change in weight for age z-score Study Day1 to Study Day 28
Secondary Gastrointestinal Tolerance Parent completed diary Study Day1 to Study Day 28
Secondary Weight Weight gain per day in grams Study Day1 to Study Day 28
Secondary Length Length gain per day in cm Study Day1 to Study Day 28
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04100460 - A Double Blind Study on the Gastrointestinal Effects of Arabinoxylan (Leaf Fiber Extract). N/A
Completed NCT00977964 - Tolerance of Healthy Term Infants Fed Infant Formulas #3 Phase 3
Not yet recruiting NCT05827198 - Evaluating the Impact of Incremental Doses of a Sugar Replacer Blend on Gastrointestinal Tolerance in Candies N/A
Completed NCT03945149 - A Clinical Trial to Evaluate the Chronic Safety and Tolerance of Turmipure Gold™ in Healthy Subjects N/A
Completed NCT03539146 - Gastrointestinal Tolerance, Satiation and Sensory Acceptance of Yogurts Containing Dietary Fiber and Coffee Cascara Extract N/A
Completed NCT02757924 - Behavior of Infants Fed Formula Supplemented With Prebiotics N/A
Completed NCT05213494 - The Effects of Soluble Corn Fiber on Gastrointestinal Tolerance and Fecal Microbiome in Healthy Children N/A
Completed NCT05051202 - A Study Assessing the Tolerable Upper Intake Level and Safety of Sugars From Fiber N/A
Completed NCT01902212 - Evaluation of an Oral Nutrition Supplement N/A
Completed NCT03597113 - Evaluation of Infants Fed an Extensively Hydrolyzed Hypo Allergenic Infant Formula
Completed NCT04745455 - Gastrointestinal Tolerance and Safety of an Infant Formula Containing Prebiotics, Probiotics and Postbiotics. N/A
Completed NCT02322138 - Gastrointestinal Tolerance of Infant Formula N/A
Completed NCT04945083 - Evaluation of a High Protein, High Calorie Pudding in Adults With/or at Risk for Malnutrition N/A
Completed NCT03648255 - TolerUp Enteral Feeding Protocol
Completed NCT03769012 - Ability of Beta-glucan Supplementation to Augment Immune Function N/A
Completed NCT02456831 - Soy Formula Feedings in Healthy, Term Infants N/A
Completed NCT03628183 - Tolerance of Infants Fed a Hydrolysate Formula N/A
Completed NCT02456805 - Alternate Formula Feedings in Formula Intolerant Infants N/A
Recruiting NCT04966299 - Effect of Daily Erythritol Versus Sucrose Intake Over 5 Weeks on Glucose Tolerance in Adolescents N/A
Completed NCT02746016 - Effect of Formula on Infant Behavior N/A